Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing
|Title:||Simethicone containing pharmaceutical compositions|
|Abstract:||A method of making solid oral dosage form for the treatment of gastrointestinal disorders comprising a therapeutically effective amount of a pharmaceutical suitable for the treatment of gastric disorders selected from the group consisting of cimetidine, ranitidine, famotidine, diphenoxylate, loperamide, loperamide-N-oxide, pharmaceutically acceptable salts thereof and combinations thereof; and a therapeutically effective amount of simethicone wherein the pharmaceutical and simethicone are separated by a barrier. The barrier is formed by coating with a polymer impermeable to simethicone.|
|Inventor(s):||Stevens; Charles A. (Lansdale, PA), Hoy; Michael R. (North Wales, PA), Roche; Edward J. (Paoli, PA)|
|Assignee:||McNeil-PPC, Inc. (Skillman, NJ)|
|Filing Date:||May 31, 1995|
|Claims:||1. A method for manufacturing a multilayered solid dosage form having one layer containing simethicone and one layer containing a pharmaceutical for treating gastric disorders selected from the group consisting of cimetidine, ranitidine, famotidine, diphenoxylate, loperamide, loperamide-N-oxide, pharmaceutically acceptable salts thereof and combinations thereof with a barrier sandwiched between the two layers comprising pressing one of two granulations each containing pharmaceutically acceptable excipients with either a therapeutic amount of simethicone or a therapeutic amount of said pharmaceutical for the treatment of a gastric disorder therein, to form a first layer with one exposed surface; forming said barrier by coating the exposed surface with a pharmaceutically acceptable polymer which is substantially impermeable to simethicone to form a coated layer with coated surface; contacting the coated surface with the remaining granulation; and pressing the granulation and coated layer to form a multilayered solid oral dosage form wherein the simethicone and the pharmaceutical are separated by the polymer substantially impermeable to simethicone. |
2. The method of claim 1 wherein the pharmaceutical comprises loperamide HCl.
3. The method of claim 1 wherein the pharmaceutical comprises diphenoxylate.
4. The method of claim 1 wherein the pharmaceutical comprises famotidine.
5. The method of claim 1 wherein the pharmaceutical comprises loperamide-N-oxide.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.